STOCK TITAN

DBV Technologies S.A. (DBVT) Stock News, Apr-Jul 2023

DBVT NASDAQ

DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.

Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.12%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
Rhea-AI Summary

DBV Technologies has outlined its regulatory path for the Viaskin Peanut 250 μg patch, targeting toddlers aged 1-3 years with peanut allergies, after receiving feedback from the FDA. The FDA confirmed that the Phase 3 EPITOPE study achieved its primary endpoint without requiring an additional efficacy study. However, a new safety study is mandated to augment existing data, aiming for a database of around 600 patients. As of March 31, 2023, the company reported cash equivalents of $192.3 million, a decrease from $209.2 million at year-end 2022. DBV is committed to developing treatment options for young children with peanut allergies, and it plans to submit a proposed protocol for the safety study to the FDA by the end of Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags

FAQ

What is the current stock price of DBV Technologies (DBVT)?

DBV Technologies (DBVT) last closed at $9.42.

What is the market cap of DBV Technologies (DBVT)?

The market cap of DBV Technologies (DBVT) is approximately $592.0M.